Artemis Medicare Services Ltd is Rated Buy

Rating Overview and Context

The current Buy rating for Artemis Medicare Services Ltd was established on 08 June 2026, when MarketsMOJO raised the stock’s Mojo Grade from Hold to Buy, accompanied by a 10-point increase in the Mojo Score from 61 to 71. This rating reflects a positive outlook on the company’s fundamentals, valuation, financial trends, and technical indicators. It is important to note that while the rating change date is fixed, all subsequent data and performance figures are as of 02 July 2026, ensuring investors have the latest insights.

Here’s How Artemis Medicare Services Ltd Looks Today

As of 02 July 2026, Artemis Medicare Services Ltd presents a compelling investment case within the hospital sector, particularly for investors seeking exposure to a smallcap healthcare player demonstrating solid growth and financial discipline. The company’s current Mojo Score of 71.0 and a Buy grade indicate a favourable risk-reward profile supported by strong operational metrics and attractive valuation.

Quality Assessment

The company’s quality grade is rated as good, reflecting robust operational performance and consistent profitability. Artemis Medicare Services Ltd has declared positive results for nine consecutive quarters, underscoring its ability to sustain earnings momentum. The latest quarterly figures show the highest net sales at ₹279.23 crores and a PBDIT of ₹51.60 crores, signalling strong operational efficiency. Additionally, the operating profit to interest coverage ratio stands at a healthy 8.10 times, indicating the company’s strong capacity to service its debt obligations without strain.

Valuation Perspective

From a valuation standpoint, the stock is considered attractive. Currently trading at a price-to-book value of 4.4, Artemis Medicare Services Ltd is priced at a discount relative to its peers’ historical averages. The company’s return on equity (ROE) of 11.3% further supports this valuation, suggesting efficient capital utilisation. Despite a PEG ratio of 3.4, which indicates moderate growth expectations relative to price, the stock’s valuation remains appealing given its consistent profit growth and market positioning.

Financial Trend Analysis

The financial trend for Artemis Medicare Services Ltd is positive, with operating profit growing at an impressive annual rate of 59.20%. This growth trajectory is a key driver behind the Buy rating, signalling strong earnings potential. Over the past year, the stock has delivered a 5.63% return, outperforming the BSE500 benchmark in each of the last three annual periods. The company’s ability to generate consistent returns while expanding profits by 28.2% over the same timeframe highlights its operational resilience and growth capacity.

Technical Outlook

Technically, the stock is rated as mildly bullish. Recent price movements show a 1.14% gain on the day and a 1.67% increase over the past week, reflecting positive investor sentiment. Although the one-month return is slightly negative at -2.30%, the three-month return of +18.64% demonstrates strong medium-term momentum. The stock’s technical indicators suggest a favourable entry point for investors looking to capitalise on its upward trend within the hospital sector.

Stock Returns and Market Performance

As of 02 July 2026, Artemis Medicare Services Ltd has delivered mixed but generally positive returns. The six-month return stands at -4.84%, while the year-to-date return is -2.07%. However, the one-year return of +5.63% and consistent outperformance against the BSE500 index over the last three years reinforce the stock’s ability to generate shareholder value over time. This performance, combined with strong fundamentals and valuation, supports the current Buy rating.

Debt and Liquidity Position

The company maintains a conservative debt profile, with a Debt to EBITDA ratio of 1.39 times, indicating manageable leverage and a strong capacity to meet financial obligations. This low leverage reduces financial risk and enhances the company’s flexibility to invest in growth opportunities or weather market volatility.

What the Buy Rating Means for Investors

MarketsMOJO’s Buy rating on Artemis Medicare Services Ltd suggests that the stock is expected to outperform the broader market over the medium term, supported by strong fundamentals and favourable valuation. Investors should view this rating as an endorsement of the company’s growth prospects, financial health, and technical momentum. The rating encourages accumulation for those seeking exposure to the hospital sector’s growth potential, especially within the smallcap space where Artemis operates.

However, investors should also consider the inherent risks associated with smallcap stocks, including liquidity constraints and market volatility. The mildly bullish technical stance indicates that while momentum is positive, prudent monitoring of price action and market conditions remains advisable.

Summary of Key Metrics as of 02 July 2026

To recap, Artemis Medicare Services Ltd currently exhibits:

• Mojo Score of 71.0 with a Buy grade
• Quality grade rated as good, reflecting operational strength
• Attractive valuation with a price-to-book of 4.4 and ROE of 11.3%
• Positive financial trend with operating profit growth at 59.20% annually
• Mildly bullish technical indicators supporting upward momentum
• Consistent positive returns outperforming BSE500 over three years
• Low Debt to EBITDA ratio of 1.39 times, indicating financial prudence

These factors collectively justify the current Buy rating and position Artemis Medicare Services Ltd as a stock worthy of consideration for investors aiming to capitalise on growth in the hospital sector.

Looking Ahead

Investors should continue to monitor quarterly results and sector developments, as Artemis Medicare Services Ltd’s ability to sustain its growth trajectory and maintain operational efficiency will be critical to realising the potential indicated by the current rating. The company’s track record of positive quarterly results and strong profit growth provides a solid foundation for future performance.

In conclusion, the Buy rating reflects a balanced assessment of Artemis Medicare Services Ltd’s quality, valuation, financial trends, and technical outlook as of 02 July 2026, offering investors a well-rounded perspective on the stock’s investment merits.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →